MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nivolumab (anti-PD-1)

CAS No. : 946414-94-4

MCE 站：Nivolumab (anti-PD-1)

产品活性：Nivolumab (anti-PD-1) 是一种 PD-1 人源类 IgG4 抗体类抑制剂，用于晚期（转移性）非小细胞肺癌的研究。

研究领域：Immunology/Inflammation

作用靶点：PD-1/PD-L1

In Vitro: Nivolumab (anti-PD-1) binds to CHO cells expressing PD-1 with an EC₅₀ of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab (anti-PD-1) binds to PD-1 on activated T cells with an EC₅₀ of 0.64 nM. Nivolumab (anti-PD-1) also inhibits the interaction between PD-1 ａnd its ligands, PD-L1 ａnd PD-L2, with IC₅₀ values of 2.52 ａnd 2.59 nM, respectively. Nivolumab (anti-PD-1) (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus.

In Vivo: Nivolumab (anti-PD-1) (10 ａnd 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 ａnd TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab (anti-PD-1) exposure increases in an approximately dose-proportional manner between 10 ａnd 50 mg/kg, with no substantial sex differences noted.

相关产品：Atezolizumab  |  Pembrolizumab  |  Nivolumab  |  BMS-1  |  BMS-202  |  Tomivosertib  |  Avelumab  |  Durvalumab  |  CA-170  |  Fraxinellone  |  BMS-1166  |  BMS-1001 hydrochloride  |  INCB086550  |  Camrelizumab  |  AUNP-12 TFA  |  BMSpep-57 hydrochloride  |  PD-1/PD-L1-IN-9  |  PROTAC PD-1/PD-L1 degrader-1  |  TPP-1  |  Sulfamethoxypyridazine  |  Human PD-L1 inhibitor V TFA  |  PD-1-IN-17  |  PD-1/PD-L1-IN-10  |  ARB-272572  |  BMS-8  |  D18

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。